Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest
CompanyDeals

Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest

Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
CompanyDrug

Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study

Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
CompanyDrug

Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment

Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
CompanyDrug

Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study

Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing
Company

Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CompanyDrug

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment

KangaBio's KGX101 Receives NMPA Approval for Clinical Trial in China
CompanyDrug

KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
Drug

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials

Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area
CompanyDrug

Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area

Junshi Biosciences' Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment
CompanyDrug

Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment

WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
Company

WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU

Juventas Cell Therapy's CAR-T Therapy Clears for SLE-ITP Study in China
CompanyDrug

Juventas Cell Therapy’s CAR-T Therapy Clears for SLE-ITP Study in China